<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770354</url>
  </required_header>
  <id_info>
    <org_study_id>AS1402-C-201</org_study_id>
    <nct_id>NCT00770354</nct_id>
  </id_info>
  <brief_title>Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer</brief_title>
  <official_title>A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination With Letrozole as First Line Treatment in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antisoma Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antisoma Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the overall tumour response rate per RECIST in
      postmenopausal women with metastatic or locally advanced breast cancer receiving AS1402 in
      combination with letrozole compared to letrozole alone
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is overall response rate (ORR)</measure>
    <time_frame>Radiological evaluations are performed every 12 weeks up to progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Radiological evaluations are performed every 12 weeks up to progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Radiological evaluations are performed every 12 weeks up to progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response and duration of stable disease</measure>
    <time_frame>Radiological evaluations are performed every 12 weeks up to progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>Radiological evaluations are performed every 12 weeks up to progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of AS1402 when combined with letrozole</measure>
    <time_frame>Radiological evaluations are performed every 12 weeks up to progression</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AS1402 plus letrozole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS1402</intervention_name>
    <description>A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>huHMFG1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Daily 2.5 mg oral letrozole tablet</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed locally advanced or metastatic breast cancer
             not amenable to curative therapy

          -  Measurable disease according to the RECIST criteria

          -  Documented estrogen receptor-positive and/or progesterone receptor-positive tumour

          -  Postmenopausal women

        Exclusion Criteria:

          -  Prior chemotherapy and/or endocrine therapy for advanced breast disease

          -  Relapse within 12 months after treatment discontinuation of an aromatase inhibitor in
             the adjuvant setting

          -  Unknown hormonal receptor status

          -  Known HER2/neu-positivity
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Acton, MA MBBS MRCP</last_name>
    <role>Study Director</role>
    <affiliation>Antisoma Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nuhad K Ibrahim, MD FACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Medical Institution</name>
      <address>
        <city>Pyatigorsk</city>
        <state>Stavropol</state>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Oncological Center</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2008</study_first_submitted>
  <study_first_submitted_qc>October 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2008</study_first_posted>
  <last_update_submitted>August 7, 2009</last_update_submitted>
  <last_update_submitted_qc>August 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Gary Acton</name_title>
    <organization>Antisoma</organization>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

